A novel epidermal growth factor receptor inhibitor for treating lung cancer

作者：Gao, Jiansheng; Liang, Yuli; Zhang, Dongying; Wang, Yi; Yang, Jiamin; Liu, Hua^*

来源：Tumor Biology, 2017, 39(4): 698358.

DOI：10.1177/1010428317698358

• Epidermal growth factor receptor
• lung cancer
• inhibitors

To investigate the effects of a novel synthetic epidermal growth factor receptor inhibitor, COMPOUND7809, on the inhibition of lung cancer growth in vitro and the underlying mechanisms, we treated three lung tumor cell lines (A549, SK-LU-1, and NCI-H23) with COMPOUND7809 and a Food and Drug Administration-approved epidermal growth factor receptor inhibitor gefitinib. Then, we examined cell growth in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, cell survival in a Cell Counting Kit-8 assay, and cell apoptosis by Annexin V flow cytometry in the presence of fluorouracil. We found that compared to gefitinib, COMPOUND7809 inhibited cell growth more potentially and induced more cell death in the presence of fluorouracil. Thus, our study demonstrates that COMPOUND7809 may be a promising epidermal growth factor receptor inhibitor for human lung cancer therapy.

• 出版日期2017-4
• 单位广东药科大学